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We investigated the effect of the conserved tyrosine-based endocytosis motif (YXXA) in the cytoplasmic domain of the human
immunodeficiency viruses (HIV) envelope protein (Env) on its immunogenicity. Genes with codons optimized for mammalian expression
were synthesized for the HIV 89.6 Env with a truncated cytoplasmic domain and a mutant Env in which the tyrosine residue in the YXXA
motif was changed into a serine. Mutation of the Tyr residue enhanced surface expression of the Env protein. Analysis of immune responses
induced by DNA immunization of mice showed that the DNA construct for the Tyr mutant Env induced moderately higher levels of T cell
responses. More interestingly, the DNA construct for the mutant Env induced significantly higher levels of antibody responses against the
Env protein in comparison to the construct for the wild type Env. Our results suggest that the YXXA motif in the HIV Env cytoplasmic
domain may play a role in virus evasion of host immune responses through affecting its immunogenicity.
D 2004 Elsevier Inc. All rights reserved.Introduction
HIV entry into cells is mediated by its envelope
glycoprotein (Freed and Martin, 1995). Being the only viral
structural protein that presents on the surface of both
infected cells and released virions, the envelope glycopro-
tein (Env) is a major target for both cellular and antibody
responses (Hunter and Swanstrom, 1990). The HIV Env
protein is synthesized as a precursor molecule (Pre) gp160
and subsequently processed into the surface subunit (SU)
gp120 and the transmembrane subunit (TM) gp41, and
exists as a trimer complex of gp120-gp41 heterodimers on
the viral or cell membrane surfaces (Earl et al., 1990; Wyatt0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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1 Contributed equally to this work.and Sodroski, 1998). The SU protein mediates interaction
with receptor and co-receptor molecules and attachment to
the cell, while the TM protein mediates fusion between viral
and cell membranes for releasing viral core components into
the cell (Doms and Moore, 2000). The TM protein contains
three distinct domains: an extracellular domain which
contains the fusion peptide and two heptad repeats; a
transmembrane domain which anchors the protein on viral
or cell membranes; and a cytoplasmic domain for which the
functions are still being elucidated.
The HIV Env protein has a long cytoplasmic domain,
which contains several structural features that have been
implicated in modulating Env protein surface expression
(Berlioz-Torrent et al., 1999; Boge et al., 1998; Bultmann et
al., 2001; Haffar et al., 1990; LaBranche et al., 1995; Rowell
et al., 1995; Wyss et al., 2001), targeting to specific
membrane microdomains for assembly (Deschambeault et
al., 1999; Lodge et al., 1994; 1997; Rousso et al., 2000;
Yang et al., 1995), interaction with the viral matrix protein004) 62–73
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et al., 1993), as well as interaction with other cellular
proteins (Berlioz-Torrent et al., 1999; Ishikawa et al., 1998;
Miller et al., 1993; Ohno et al., 1997; Wyss et al., 2001). Of
these, a membrane proximal Tyr-based YXXA endocytosis
motif (amino acids 710–713 in the HIV 89.6 Env protein),
in which A represents a hydrophobic amino acid with a
large aliphatic side chain (a Leu residue in HIV 89.6 Env),
has been characterized extensively. This YXXA motif is
highly conserved in the cytoplasmic domain of the envelope
proteins of HIV-1, HIV-2, and SIV, as well as glycoproteins
of other retroviruses (Marsh and Pelchen-Matthews, 2000).
It has been shown that the YXXA motif in the HIV Env
protein serves as a sorting signal that mediates polarized
release of HIV virions from basolateral surfaces of epithelial
cells, and polarized release of HIV as well as simian
immunodeficiency virus (SIV) virions from specific loca-
tions of plasma membranes of lymphocytes (Deschambeault
et al., 1999; Lodge et al., 1994; 1997;). The YXXA motif
also functions as a potent endocytosis signal through
interactions with the cellular clathrin adaptor protein AP-2
that has been shown to bind specifically to this motif (Boge
et al., 1998). Moreover, the YXXA motif has also been
implicated in HIV and SIV Env protein membrane fusion
activity, Env incorporation into virions, virus infectivity, and
processing and presentation by the cellular machinery to the
immune system (Cervantes-Acosta et al., 2001; Day et al.,
2004; LaBranche et al., 1994; 1995; Rowell et al., 1995;
Sauter et al., 1996; West et al., 2002). Recently, it was
reported that disruption of the YXXA motif by mutation of
the Tyr residue in the SIVmac239 Env protein led to
attenuation in virus replication and pathogenesis during in
vivo infection of rhesus monkeys, although the mutant virus
exhibits similar levels of infectivity and cytopathicity to
those of the wild type SIVmac239 in cell cultures (Fultz et
al., 2001). The underlying mechanism for this discrepancy
between in vitro infectivity and in vivo pathogenesis
remains to be determined. In this study, we examined the
effect of mutating the Tyr residue in this YXXA motif on
immunogenicity of the HIV Env protein in the context of
DNA immunization, which mimics viral protein synthesis,
processing, and presentation during infection. We report that
mutation of the conserved Tyr residue exerts a profound
effect on immunogenicity of the HIV Env protein, indicat-
ing a potential mechanism, which may be employed by HIV
to evade the immune system.Fig. 1. Schematic diagram for the HIV 89.6 Env proteins encoded by
synthetic genes. Codon-optimized genes for HIV 89.6 EnvTr and EnvTr/
Y710S were synthesized as described in Materials and methods. Amino
acid sequence for the truncated cytoplasmic domain is shown. The Tyr
residue in the YXXA motif and the Ser residue in the mutant are
underlined.Results
Mutation of the Tyr residue in the YXXA motif of the HIV
89.6 Env with a truncated cytoplasmic domain enhances
Env protein surface expression
The long cytoplasmic domain of the HIV Env protein
contains multiple determinants that modulate its surfaceexpression and mediate interaction with other cellular
proteins (Bultmann et al., 2001; Rowell et al., 1995; Wyss
et al., 2001). Thus, to examine the specific function of the Tyr
residue, we constructed an HIV 89.6 Env with a truncated
cytoplasmic domain (18 amino acids in length) to eliminate
the possible impact of other sequences in the cytoplasmic
domain. Early studies have shown that synthetic HIV env
genes with codons optimized for mammalian expression
allows for greatly increased, Rev-independent expression of
the HIV Env proteins and the use of such constructs has been
shown to enhance immunogenicity in DNA immunization
(Andre et al., 1998; Haas et al., 1996; zur Megede et al.,
2000). Therefore, we synthesized a codon-optimized gene
for the truncated HIV 89.6 Env containing 18 amino acids in
the cytoplasmic domain (designated as EnvTr) by PCR
assembly of long oligonucleotides (110 bases in length) as
described in our previous studies (Bu et al., 2003).
Deschambeault et al. (1999) showed that replacing the Tyr
residue into a serine exerted a more pronounced effect on
surface expression of HIV Env than changing it into an
alanine. Thus, to investigate whether the YXXA motif could
affect the HIV Env immunogenicity, the Tyr residue in the
HIV 89.6 EnvTr was mutated into Ser (designated as EnvTr/
Y710S) by site-directed PCR mutagenesis. A schematic
diagram of these proteins is shown in Fig. 1.
The synthetic genes were cloned into the plasmid vector
pCAGGS under the control of the chicken g-actin promoter,
and protein expression by these DNA constructs was
assessed in HeLa cells as described in Materials and
methods. We first examined protein expression by contin-
uous radioactive labeling followed by surface biotinylation
and immunoprecipitation. As shown in Fig. 2A, both EnvTr
and EnvTr/Y710S were expressed at similar levels in the
cell and the amount of gp120 (SU) secreted into the medium
was also similar for both constructs. However, in compar-
ison to EnvTr, the mutant EnvTr/Y710S was expressed at
significantly higher levels on cell surface. To determine
whether the lower levels of surface expression for EnvTr is a
result of a decrease in transport to the cell surface or a
decrease in surface stability, we carried out pulse-chase
radioactive-labeling followed by surface biotinylation and
immunoprecipitation. As shown in Fig. 2B, similar levels of
    
Fig. 2. A. Enhanced surface expression of the mutant EnvTr/Y710S protein. HeLa cells were transfected with the DNA constructs using Lipofectamine2000. At
24 h post transfection, the cells were labeled with 35S-Met, Cys labeling mix for 6 h followed by surface biotinylation and immunoprecipitation as described in
Materials and methods. Protein samples were prepared and analyzed by SDS-PAGE. Lanes 1, Plasmid vector pCAGGS; 2, EnvTr; 3, EnvTr/Y710s. Pre, HIV
Env precursor Gp160; SU, surface subunit Gp120; TM, transmembrane subunit Gp41. B. Analysis of protein stability on cell surfaces by pulse-chase
radioactive labeling and immunoprecipitation. Protein expression was carried out by transfection of HeLa cells. At 24 h post transfection, the cells were pulse
labeled with 35S-Met, Cys labeling mix for 1 h and then chased in complete medium for 2, 4, or 6 h followed by surface biotinylation and immunoprecipitation
as described in Materials and methods. Protein samples were prepared and analyzed by SDS-PAGE. Lanes 1, Plasmid vector pCAGGS; 2, EnvTr, pulse only; 3,
EnvTr, 2 h chase; 4, EnvTr, 4 h chase; 5, EnvTr, 6 h chase; 6, EnvTr/Y710S, pulse only; 7, EnvTr/Y710S, 2 h chase; 8, EnvTr/Y710S, 4 h chase; 9, EnvTr/
Y710S, 6 h chase.
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EnvTr and EnvTr/Y710S after the 1-h pulse as well as at
different chase time points. However, surface expression of
EnvTr/Y710S is higher compared to that of EnvTr at all
chase time points and more so after 6 h chase as indicated
by the amount of TM protein detected on the cell surface.
The amount of TM protein on the cell surfaces is considered
to reflect the levels of HIV Env protein surface expression
more accurately since the shedding of SU protein can occur.
These results are consistent with the results from continuous
labeling shown in Fig. 2A. Moreover, surface expression of
EnvTr TM exhibited a sharp decrease at the 6-h chase time
point (comparing lanes 3, 4, and 5 in Fig. 2B surface
expression), indicating reduced surface stability. Taken
together, these results indicate that mutation of the Tyr
residue in the YXXA motif increases Env protein surface
expression and also enhances its stability on cell surface.
Effect of Tyr mutation on induction of CD8 T cell responses
against a dominant epitope in HIV 89.6 Env
To determine the effect of the Y710S mutation on
immunogenicity of the HIV 89.6 Env protein, we immu-
nized mice with the DNA constructs EnvTr, EnvTr/Y710S,or pCAGGS (vector control), and compared immune
responses induced by these constructs. Balb/c mice (groups
of 6) were immunized at weeks 0 (prime) and 4 (boost), and
sacrificed at week 6 for analysis of immune responses. The
CD8 T cell response against a dominant epitope in the HIV
89.6 Env for Balb/c mice was determined by stimulation of
splenocytes from each mouse with the peptide followed by
intracellular cytokine (ICC) staining and flow cytometry.
Shown in Fig. 3A are the gating of CD4 and CD8 T cells
from mouse splenocytes and background levels of IFNg
production by stimulation with an irrelevant peptide. Shown
in Fig. 3B are the representative results for the levels of
IFNg producing CD8 T cells from immunized mice after
stimulation by the peptide IGPGRAFYAR corresponding to
the dominant epitope of the HIV 89.6 Env protein (amino
acids 312–321) for Balb/c mice, and the average level of
IFNg producing CD8 T cells for each group is shown in Fig.
3C. As shown in Fig. 3, the levels of IFNg producing CD8
T cells in splenocytes from mice immunized with EnvTr or
EnvTr/Y710S are similar, whereas splenocytes from mice
immunized with the control vector pCAGGS only showed
background levels of IFNg expression, similar to the levels
of IFNg producing CD8 T cells from mice immunized with
EnvTr or EnvTr/Y710S stimulated by the control peptide
Fig. 3. Comparison of CD8 T cell responses induced by DNA immunization against a dominant epitope in the HIV 89.6 Env protein. Groups of BALB/c mice
(6 per group) were immunized i.m. with 100 Ag of pCAGGS (vector control), EnvTr, or EnvTr/Y710S at weeks 0 and 4. At week 6, mouse splenocytes were
collected and stimulated with the peptide IGPGRAFYAR (10 Ag/ml) for 6 h at 378C. The cells were then stained for cell surface CD4 (FITC) and CD8 (PerCP)
as well as intracellular IFNg, and analyzed by flow cytometry. Background IFNg-producing cells were determined by culturing mouse splenocytes with an
irrelevant peptide (AMQMLKETI). Values in each box are the percentage of the gated population. (A) Gating of CD8 and CD4 lymphocytes and background
IFNg production by CD8 or CD4 lymphocytes stimulated with the peptide AMQMLKETI (Control). (B) Representative results of FACS analysis for IFNg
production by CD8 T cells from each immunization group stimulated with the peptide IGPGRAFYAR. Numbers in lower-right boxes represent percentages of
IFNg staining positive CD8 T cells. (C) Percentages of IFNg staining positive CD8 T cells for each immunization group after stimulation with the peptide
IGPGRAFYAR. D. Analysis of CD8 T cell responses by IFNg ELISPOT. Splenocytes from mice immunized with indicated DNA constructs were seeded into
ELISPOT plates (106 per well) and stimulated for 16 h using the peptide IGPGRAFYAR. IFNg producing cells (spots) were detected and counted as described
in Materials and methods.
Z. Bu et al. / Virology 328 (2004) 62–73 65
Z. Bu et al. / Virology 328 (2004) 62–7366AMQMLKETI, which corresponds to an epitope in the HIV
Gag protein (Qiu et al., 2000). Shown in Fig. 3D are the
results of ELISPOT analysis for IFNg producing T cells
stimulated by the peptide IGPGRAVFTI, showing that
similar numbers of spots were detected for splenocytes
from mice immunized with EnvTr or EnvTr/Y710S, in
agreement with the results from ICC staining and FACS
analysis. These results indicate that mutation of Tyr residue
did not significantly affect the induction of CD8 T cell
responses against the dominant epitope in the HIV 89.6 Env
protein in DNA immunization.
Effect of Tyr mutation on induction of broad T cell responses
against HIV 89.6 Env
We next examined the ability of the splenocytes from
immunized mice to produce IFNg when stimulated with
peptide pools corresponding to the HIV-1 89.6 Env protein.
Peptide pools (obtained from the NIH AIDS Research andFig. 4. Analysis of CD8 T cell responses by stimulation with peptide pools. Mo
aliquots were stimulated for 16 h using each of the peptide pools covering the e
incubation of 5 h and then stained for surface CD4 (FITC) and CD8 (PerCP) and
negative population as shown in Fig. 3A. Y axle, staining for cell surface CD4 (neg
lower-right boxes represent percentages of IFNg producing CD8 T cells. The Pep
pool 2, A.A. 200–410; pool 3, A.A. 400–610; and pool 4, A.A. 600–853.Reference Reagent Program) consisted of 20 mers over-
lapping by 10 amino acids and were divided into four pools
covering the entire Env protein. Due to the limited supply of
peptide pool and number of samples, mouse splenocytes
from each group were pooled for these studies. As shown in
Fig. 4, peptide pool 2, which covers the region in the Env
protein from amino acid 200 to 400 and contains the
dominant epitope, stimulated similar levels of IFNg
producing CD8 T cells (2.35% for EnvTr and 2.76% for
EnvTr/Y710S). These levels were higher compared with
stimulation with the dominant peptide, probably due to the
addition of more peptide for cell stimulation (20 peptides
per pool with 5 Ag/ml for each peptide) and/or longer
stimulation time needed for stimulation with the peptide
pools. Nonetheless, this result is in agreement with the result
obtained with stimulation with the dominant peptide in that
similar levels of IFNg producing CD8 T cells were
stimulated for splenocytes from mice immunized with
EnvTr or EnvTr/Y710S. However, immunization of miceuse splenocytes from each group were pooled and the pooled splenocytes
ntire HIV 89.6 Env protein, followed by addition of brefeldin A, a further
intracellular IFNg (APC). The cells were gated as CD8-positive and CD4-
ative in this population); X axle, staining for intracellular IFNg. Numbers in
tide pools are 20 mers overlapping by 10 amino acids. Pool 1, A.A. 1–210;
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producing cells against subdominant epitopes. As also
shown in Fig. 4, stimulation with the peptide pools 1 and
3 induced about 1.11% and 0.45% of CD8 T cells producing
IFNg in splenocytes from EnvTr/Y710S immunized mice,
versus 0.47% and 0.3%, respectively, in splenocytes from
EnvTr immunized mice. Stimulation with the peptide pool 4
did not induce significant levels of IFNg producing CD8 T
cells in splenocytes from mice immunized with either
construct, probably due to lack of CD8 epitopes in this
region. These results indicate that mutation of the Tyr
residue may moderately augment induction of CD8 T cell
responses against subdominant epitopes.
The use of peptide pools for stimulation also allowed us
to compare CD4 T cell responses induced by immunization
with different DNA constructs. As shown in Fig. 5, the
levels of CD4 T cell responses from the Tyr mutant Env
construct immunized mice were increased in comparison to
the wild type Env construct immunized mice, although the
increase was less pronounced. Stimulation with the peptideFig. 5. Analysis of CD4 T cell responses by stimulation with peptide pools. Mo
aliquots (2  106 per well in 48-well plate) were stimulated for 16 h using each o
addition of brefeldin A, a further incubation of 5 h and then stained for surface C
gated as CD4-positive and CD8-negative population as shown in Fig. 3A. Y axle,
for intracellular IFNg. Numbers in lower-right boxes represent percentages of IFN
amino acids. Pool 1, A.A. 1–210; pool 2, A.A. 200–410; pool 3, A.A. 400–610;pools 1, 2, and 3 induced IFNg producing CD4 T cells at
0.57%, 0.65%, and 0.4% for EnvTr-immunized mice and
0.84%, 0.97%, and 0.41% for EnvTr/Y710S immunized
mice, respectively. Again, stimulation with the peptide pool
4 did not induce significant levels the IFNg producing cells
above background and in comparison to the control vector
immunized mice. Thus, induction of CD4 T cell responses
against HIV Env by DNA immunization is also moderately
enhanced by mutation of the Tyr residue.
The DNA construct EnvTr/Y710S is more potent in eliciting
antibody responses against the HIV Env protein
To compare the humoral immune responses induced by
DNA immunization, sera from immunized mice were
collected at 2 weeks post final immunization and analyzed
for antibodies against HIV 89.6 gp120 by ELISA. As shown
in Fig. 6A, sera from mice immunized with EnvTr showed
lower levels of antibody responses against the HIV 89.6
gp120, about 1400 ng/ml on average. On the other hand,use splenocytes from each group were pooled and the pooled splenocytes
f the peptide pools covering the entire HIV 89.6 Env protein, followed by
D4 (FITC) and CD8 (PerCP) and intracellular IFNg (APC). The cells were
staining for cell surface CD8 (negative in this population); X axle, staining
g producing CD4 T cells. The peptide pools are 20 mers overlapping by 10
and pool 4, A.A. 600–853.
Fig. 6. DNA immunization with EnvTr/Y710S elicited enhanced antibody responses. Sera from mice immunized with different DNA constructs were collected
at 2 weeks post immunization and analyzed for antibodies specific for HIV 89.6 Env protein by ELISA as described in Materials and methods. The levels of
antibody responses are expressed as the quantity of antibodies binding to HIV 89.6 gp120 in 1 ml sera from each mouse. (A) ELISA for total IgG. (B) ELISA
for subtype IgG1. (C) ELISA for subtype IgG2a. The results were analyzed by the Microsoft Excel program and error bars indicate the standard deviations for
each immunization group. (D) Neutralization of HIV 89.6 by sera from immunized mice. Sera from immunized mice were mixed with HIV 89.6 and
neutralization of HIV 89.6 was analyzed in JC53-BL cells as described in Materials and methods. The percentages of neutralization by each serum sample were
calculated and compared. The average neutralization value and standard deviation were shown for each group. The P values obtained for statistical comparison
between EnvTr or EnvTr/Y710S immunized mice with pCAGGS immunized mice are also shown.
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fold higher levels of antibody responses against gp120, with
an average of about 8000 ng/ml. Thus, the DNA construct
for the Tyr-mutant EnvTr/Y710S is much more effective in
inducing humoral immune responses. We next compared the
different isotypes of antibody responses. As shown in Figs.
6B and 6C, immunization with EnvTr/Y710S induced
higher levels of IgG1 as well as IgG2a antibodies against
HIV 89.6 gp120 than immunization with EnvTr, with a 9-
fold increase for IgG1 (400 ng/ml vs. 3600 ng/ml for EnvTr
and Env Tr/Y710S, respectively) and about 18-fold increase
for IgG2a (about 120 ng/ml vs. 2200 ng/ml for EnvTr and
Env Tr/Y710S, respectively). Thus, mutation of the Tyr
residue into a Ser residue renders the HIV Env DNAvaccine
much more potent in eliciting both isotypes of antibodies,
with a more pronounced increase for IgG2a. This translates
into an approximately 2-fold reduction in IgG1/IgG2a ratio
in mice immunized with EnvTr/Y710S in comparison to
mice immunized with EnvTr. These results demonstrate that
the EnvTr/Y710S construct is more potent in comparison to
the EnvTr construct in inducing antibody responses with a
bias for Th1 type immune responses, which typically exhibit
a reduced IgG1/IgG2a ratio (Raz et al., 1996; Romagnani,
1997).
To determine whether induced antibody responses by
DNA immunization are biologically active, we comparedneutralizing activities of mouse sera against single-round
HIV 89.6 infection of an indicator cell line JC53-BL, which
is a derivative of HeLa cells that expresses high levels of
CD4 and CCR5 and CXCR4 and also contains a h-
galactosidase reporter cassette that is expressed from an
HIV-1 LTR dependent on production of HIV-1 Tat (Derdeyn
et al., 2000). As shown in Fig. 6D, at 1:80 dilution, sera
from both EnvTr and EnvTr/Y710S immunized mice
exhibited higher levels of neutralizing activity on average
against HIV 89.6 compared with sera from mice immunized
with the control vector pCAGGS. Moreover, sera from
EnvTr/Y710S immunized mice show the highest level of
neutralizing activity which is significantly higher than the
sera from control group mice (P = 0.01). Although sera
from EnvTr/Y710S immunized mice exhibited higher levels
of neutralizing activity than sera from EnvTr immunized
mice, the differences are not statistically significant.Discussion
In this study, we investigated the effect of the conserved
YXXA motif in the cytoplasmic domain of the HIV Env
protein on the immunogenicity of the HIV Env protein in
the context of DNA immunization. Our results show that
mutation of the Tyr residue in the YXXA motif into a serine
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protein with a truncated cytoplasmic domain (18 amino
acids in length). Pulse-chase radioactive labeling and
immunoprecipitation studies show that the enhanced surface
expression for the Tyr mutant resulted from an observed
increase in surface stability due to disruption of the YXXA
endocytosis motif. Evaluation of immune responses induced
by DNA immunization of mice showed that mutation of the
Tyr residue in the YXXA motif did not affect induction of
the CD8 T cell response against a known dominant epitope
in the HIV 89.6 Env protein, but moderately enhanced
induction of CD8 T cell responses against subdominant
epitopes as well as CD4 T cell responses. Interestingly, the
DNA construct for the Tyr mutant, EnvTr/Y710S, is
significantly more potent in eliciting antibody responses
with a stronger bias towards Th1 type immune responses.
Moreover, sera from EnvTr/Y710S immunized mice
showed significantly higher levels of neutralizing activity
against HIV 89.6 when compared with sera from the control
group. These results suggest that the YXXA motif may play
a role in affecting the immunogenicity of the HIV Env
protein and thus help HIV to evade the immune system.
The conserved YXXA motif in the HIV Env protein
cytoplasmic domain has been reported to affect the site for
virus particle budding, incorporation of Env protein into
virions, and infectivity of released virions (Ball et al., 1997;
Day et al., 2004; Deschambeault et al., 1999; Lodge et al.,
1994; 1997; West et al., 2002). The results obtained in this
study show that disrupting the YXXA motif of the HIV Env
protein strongly affects its ability to elicit antibody
responses. Since mutation of Tyr-710 did not affect cellular
expression of the HIV Env protein or secretion of gp120,
these results indicate that the observed differences in
immune responses may be due to the change in surface
stability of Env protein by the mutation. It is possible that
rapid endocytosis of HIV Env proteins from the surface of
antigen presenting cells may lead to reduced exposure of
Env antigens to B cell receptors and therefore decrease
stimulation of antibody production. Alternatively, it is also
possible that mutation of Tyr-710 may alter specific local-
ization of the Env protein on the plasma membrane as
observed for HIV virus assembly in epithelial cells and
lymphocytes and thus affect stimulation of B cells.
We did not observe a significant difference in induction
of CD8 T cell responses against a dominant epitope in the
HIV 89.6 Env protein for Balb/c mice. On the other hand,
mutation of Tyr-710 moderately enhanced induction of CD8
T cells against potential subdominant epitopes as well as
IFNg producing CD4 T cells, as determined by stimulation
using peptide pools. Previous studies have shown that
mutation of the Tyr residue in the YXXA motif does not
significantly affect processing and presentation of the HIV
Env protein for recognition by CD4 T cells in an in vitro
system (Rowell et al., 1995). It was hypothesized that the
cells may employ alternative mechanisms for antigen
processing and presentation. However, it is possible thatthese alternative mechanisms may differ in their effective-
ness to elicit immune responses. Fernandes et al. (2000)
reported that while similar numbers of peptide epitopes were
generated for ovalbumin targeted to the endocytosis path-
way or lysosomes, the efficiency for presentation of each
peptide epitope was found to be different between the two
targeting strategies. Nonetheless, the observed modest
enhancement of T cell responses may play a role in the
observed effect of the Tyr mutation on IgG2a induction by
providing more IFNg producing Th1 helper T cells
(Romagnani, 1997).
HIV has been shown to employ several strategies to
evade the immune system. Previous studies have shown that
HIV expresses a regulatory protein Nef, which down-
regulates surface expression of MHC I molecules in infected
cells and thus enables these cells to evade recognition by
cytotoxic T cells (Cohen et al., 1999; Collins et al., 1998;
Mangasarian et al., 1999; Schwartz et al., 1996). Further-
more, it was reported that in HIV infected cells Fas ligand
expression was increased, which led to killing of adjacent T
cells through Fas-mediated apoptosis (Geleziunas et al.,
2001; Xu et al., 1999). Moreover, it is well known that the
error-prone reverse transcriptase of HIV results in rapid
production of mutant viruses that effectively evade pre-
viously induced immune responses, both cytotoxic T cells
and neutralizing antibodies. Our results indicate yet another
potential mechanism, which may be employed by HIV to
escape recognition by the immune system. It is interesting to
note that the presence of a Tyr-based endocytosis motif in
the Env protein cytoplasmic domain is well conserved
among retroviruses (Marsh and Pelchen-Matthews, 2000).
Future studies to determine whether this represents a
common mechanism for retroviruses to evade the immune
system shall increase our understanding of the interplay
between retrovirus infection and host immune responses.
Induction of both cellular and humoral immune
responses against HIV infection is critical for the develop-
ment of an effective AIDS vaccine (Letvin et al., 2001;
Nabel, 2001). DNA immunization followed by boosting
with recombinant virus-based vaccines has been shown to
induce strong, long-lasting T cell immune responses
against HIV antigens, and such T cell responses have been
shown to control peak viremia and disease progression
after challenge with pathogenic viruses in non-human
primates (Amara et al., 2001; Rose et al., 2001; Shiver
et al., 2002). In comparison, the induction of an effective
antibody response against the HIV Env protein has been
less successful, in both the quality and intensity of the
response. Since both DNA vaccines and recombinant virus-
based vaccines elicit immune responses by direct expres-
sion of foreign antigens, it is possible that the presence of
the conserved endocytosis signal in the HIV Env cyto-
plasmic domain in these vaccines leads to induction of sub-
optimal antibody responses. Our results show that immu-
nization with an HIV Env DNA vaccine with mutation of
the Tyr residue in the YXXA motif also induced
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be interesting to determine whether the use of DNA
vaccines or recombinant virus-based vaccines expressing
mutant HIV Env proteins with disruption of the conserved
YXXA motif will elicit stronger antibody responses in
non-human primate models, which are more relevant for
evaluation of AIDS vaccines to assess whether such
mutations will affect the quality of the antibody response,
that is, induction of neutralizing antibodies. Further
understanding of the mechanism by which the endocytosis
motif modulates immunogenicity of the HIV Env protein
may lead to the development of new strategies to overcome
the difficulties in inducing effective antibody responses for
AIDS vaccine development.Materials and methods
Synthesis of codon-optimized genes for the wild type and
mutant HIV Env proteins
A synthetic gene for a truncated HIV 89.6 Env protein
containing 18 amino acids in the cytoplasmic domain with
codons optimized for mammalian usage was synthesized by
PCR assembly of long single strand DNA templates (110
bases in length) as described in our previous studies (Bu et
al., 2003). Briefly, the templates were designed based on
preferred mammalian codons for each amino acid as
described by Haas et al. (1996), and used to generate
overlapping short DNA fragments of about 200 bases in
length. These DNA fragments were then linked together by
step-wise overlapping PCR to generate larger fragments and
then finally the entire gene. Mutation of the codon for the
Tyr residue was carried out by site-directed PCR muta-
genesis. All genes were confirmed by sequencing and then
cloned into a plasmid vector pCAGGS (kindly provided by
Dr. Y. Kawaoka) under the control of a chicken h-actin
promoter. The sequence for the codon-optimized HIV 89.6
env gene has been submitted to GeneBank (access number
AY641097).
Protein expression analysis
Protein expression was analyzed by radioactively label-
ing and immunoprecipitation followed by SDS-PAGE.
HeLa cells were transfected with appropriate DNA con-
structs by Lipofectamine 2000 (GIBCO-BRL) following the
manufacturer’s protocol. At 24-h post transfection, cells
were starved in Met, Cys-deficient DMEM for 30 min and
then labeled with 35S-Met, Cys labeling mix (Amersham)
for a period of time as specified for each experiment in
figure legends. The cells were then chased in complete
DMEM and lysed with lysis buffer at different time point,
and then precipitated with anti-serum against HIV-1 89.6
Env and Protein A-agarose beads (Pierce). The surface
expression of the HIV Env protein was detected by a surfacebiotinylation assay (Yang and Compans, 1996). Briefly,
after labeling and chase, cells were washed with PBS at 4 8C
and then incubated with 1 ml NHS-SS-Biotin dissolved in
PBS (1 mg/ml) for 30 min at 4 8C. The cells were then
washed and lysed and the Env proteins were immunopre-
cipitated with antibodies and Protein A agarose beads
overnight at 4 8C. Proteins bound to protein A were washed
three time with lysis buffer and the beads were added with
10% SDS and heated at 95 8C for 15 min. Dissociated
proteins were precipitated again with streptavidin agarose
beads at 4 8C for 3 h and then washed three times with lysis
buffer. Protein samples were then prepared by addition of
reducing sample buffer, heated at 95 8C for 5 min before
analysis by SDS-PAGE.
Immunization of mice
Female BALB/c mice (H-2d) 6–8 weeks of age were
purchased from Charles River Laboratory. Plasmids were
amplified in Escherichia coli DH5a and purified with a
Qiagen Endo-Free Megaprep kit. The plasmids were then
resuspended at 1 Ag/Al in sterile PBS and stored at 80 8C
until used for immunization. Groups of mice (six per group)
were immunized with a total of 100 Ag of indicated DNA
construct per mouse by intra-muscular injection with 50 Al
of DNA in separate sites in both side quadriceps, followed
by boosting with the same dose of DNA at week 4.
Flow cytometry analysis of immune responses
At 14 days after the boosting DNA immunization, mice
were sacrificed and spleens were removed, homogenized,
and compressed through a sterile nylon membrane. Mouse
splenocytes were prepared by lysis of red blood cells with
ammonium chloride and washed twice with RPMI 1640.
The cells were resuspended in complete culture medium
(RPMI 1640 plus 10% fetal calf serum, 50 AM h-
mercaptoethanol, and antibiotic mix) and the cell viability
was determined by trypan blue exclusion. For assessment of
CD8 T cell response to a known dominant epitope in the
HIV-1 89.6 Env for Balb/c mice, prepared splenocytes (106
cells per well in a 96-well plate) were incubated with the
peptide IGPGRAFYAR (10 Ag/ml) for 5 h in the presence of
brefeldin A (10 Ag/ml). Cells cultured with an irrelevant
peptide (AMQMLKETI) corresponding to an H-2d
restricted CTL epitope of the HIV Gag protein were used
as negative controls (Qiu et al., 2000). For analysis of broad
CD8 and CD4 T cell responses, cells (106 per sample) were
cultured with pools of peptides (20 mers overlapping by 10
amino acids) corresponding to the HIV-1 89.6 Env protein
(obtained from the NIH AIDS Research and Reference
Reagent Program) for 16 h and then incubated with
brefeldin A (Sigma, 10 Ag/ml) for an additional 5 h. After
stimulation, the cells were washed twice with PBS contain-
ing 3% fetal calf serum and then stained with FITC-
conjugated rat anti-mouse CD4 and PerCP-conjugated rat
Z. Bu et al. / Virology 328 (2004) 62–73 71anti-mouse CD8 antibodies (Pharmingen). Cells were then
fixed and permeabilized with cytofix buffers (Caltag) and
then stained for intracellular IFNg using APC-conjugated
rat anti-mouse IFNg antibody (Pharmingen). Flow cytom-
etry analysis was performed on a BD FACSCalibre with
CELLQuest software and data was analyzed using Flowjo
4.2 software.
Enzyme-linked immunosorbent spots (ELISPOTs) assay
A purified rat anti-mouse IFNg monoclonal antibody R4-
6A2 (PharMingen) was used to coat Multiscreen 96 well
filtration plates (Millipore, Bedford, MA), respectively, at 4
Ag/ml in PBS at 4 8C overnight. Coated plates were washed
with 0.05% Tween-20 in PBS (PBST) before 200 Al of 10%
FCS in RPMI 1640 was added to each well for 2 h at 37 8C
to block nonspecific binding. Freshly prepared splenocytes
(1  106 cells) in 100 Al of complete medium with the
peptide IGPGRAFYAR (10 Ag/ml) were placed in each well
and incubated at 37 8C for 24 h. Plates were washed with
PBST and overlaid with 50 Al (2 Ag/ml) of biotinylated anti-
mouse IFNg monoclonal antibody (XMG1.2, Pharmingen)
24 h at 4 8C. The plates were then washed six times with
PBST and treated with avidin-conjugated with horse radish
peroxidase (HRP) (Pharmingen) at 1:1000 dilution for 2 h at
RT. After extensive washing, stable DAB (Research
Genetics) was added to develop spots in the plates for 30
min. The plates were rinsed with water and then air-dried,
and the spots were counted in an ImmunoSpot ELISpot
reader (Cellular Technology).
ELISA
Mouse blood was collected by retro-orbital bleeding at
14 days after final DNA immunization. 96-well plates were
coated with purified HIV-1 89.6 gp120-Histag (prepared by
Nicald affinity purification using a Qiagen kit, 3 Ag/ml in
borate-buffered saline, pH 8.5, 100 Al per well) at 4 8C
overnight and blocked with PBS-T-BSA (phosphate-
buffered saline, 0.1% Tween-20, 3% bovine serum album)
for 3 h at 37 8C. Serial dilutions of mouse serum were then
added to each well in triplicate and incubated at 37 8C for
3 h. HRP-conjugated secondary antibody (Sigma) against
mouse IgG was added for 2 h at 37 8C. After a final wash,
ABTS (2,2’-azino-bis(3-ethybenz-thiazoline-6-sulfonic
acid), Sigma) dissolved in citrate phosphate buffer (3 mg
ABTS in 10 ml CPB, pH 4.2, plus 10 Al H2O2) was added
at 100 Al/well for developing color and read by an ELISA
reader at 405 nm. A standard curve for absorbance and the
amount of mouse antibody absorbed to the well was
obtained by coating ELISA plates with serial 2-fold
dilutions of purified mouse antibodies followed by addition
of HRP-conjugated secondary antibody and development
of color. Data were analyzed by a Microsoft Excel program
and presented as the equivalent amount of Env-binding
antibodies in mouse sera (ng/ml).Neutralizing antibody assay
A neutralizing antibody assay was performed using a
highly sensitive, single round infectivity assay as described
by Derdeyn et al. (2000). The assay is based on an indicator
cell line, JC53-BL (kindly provided by Tranzyme, Inc.).
Briefly, JC53BL cells were seeded at 40,000 cells per well
in a 96-well plate in 10% FCS-DMEM media overnight at
37 8C with 5% CO2. Serum samples from mice were heat
inactivated at 56 8C for 30 min and diluted 1:40 in 10%
FCS-DMEM to final volume of 25 Al and added to 25 Al of
virus stocks diluted in 10% FCS-DMEM containing 50
infectious particles (final serum dilution 1:80). Viruses
mixed with medium only were used as controls. The virus-
serum mixtures were prepared in triplicates and incubated at
37 0C for 1 h and then added to the JC53-BL cells with
DEAE-dextran (final concentration, 15 Ag/ml). After 2 h of
incubation, an additional 200 Al of 10% FCS-DMEM was
added. Three days after infection, the medium was removed
and the cells were fixed and stained as described in our
previous studies (Vzorov and Compans, 2000). Neutraliza-
tion was calculated as: (average number of blue foci in
control wells-average number of blue foci in virus  serum
mixture sample wells) / (average number of blue foci in
control wells)  100%. Data were analyzed by a Microsoft
Excel program and presented as percentage of neutralization
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